About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

351,441 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 10/30/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 10/30/2020.
Our Science
  • Immuno-Oncology

    The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

     

    Celgene is exploring immuno-oncology therapies targeting multiple cell types associated with anti-tumor responses. In collaboration with key partners, Celgene is investigating B-cell functions relevant to tumor immunology,1,2 stimulating T-cell immunity against hematologic and solid tumors,3-6 modulating innate immunity5-8 and NK cell function to enhance tumor cell killing,9,10 reducing immunosuppressive effects of suppressor cells,9,10 and modulating the metabolic state of immune cells and the tumor microenvironment to stimulate antitumor response in cancer patients.11,12 Although tumor cells use multiple mechanisms to evade immune response3,4,13 development of these immunotherapeutic approaches may assist in the elimination of tumor cells by the immune system.

    Targeting Multiple Immune Cell Types in Immuno-Oncology

    Researching the Modulation of the Immune System to Attack Cancer Cells

    References

    1. Namm JP, et al. J Surg Oncol. 2012;105:431-435. PMID: 21898417
    2. Lapalombella R, et al. Blood. 2010;115:2619-2629. PMID: 19965642
    3. Disis M. Semin Oncol. 2014;41:S3-S13. PMID: 25438997
    4. Harris TJ, Drake CG. J Immunother Cancer. 2013;1:12. PMID: 24829749
    5. Pardoll DM. Nat Rev Cancer. 2012;12:253-264. PMID: 22437870
    6. Gandhi AK, et al. Br J Haematol. 2014;164:811-821. PMID: 24328678
    7. Weiskopf K, et al. Science. 2013;341:88-91. PMID: 23722425
    8. Herter S, et al. J Immunol. 2014;192:2252-2260. PMID: 24489098
    9. Zhang L, et al. Am J Hematol. 2009;84:553-559. PMID: 19565649
    10. Kang L, et al. Front Immunol. 2013;4:1-13. PMID: 23641243
    11. Young A, et al. Cancer Discovery. 2014;4:879-888. PMID: 25035124
    12. Pearce EL, et al. Science. 2013;342:1242454. PMID: 24115444
    13. Corthay A. Front Immunol. 2014;5:1-8. PMID: 24860567